Winton Group’s LENZ Therapeutics LENZ Stock Holding History

Winton Group’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,131	Closed	-$332K	–	1144
2025 Q3	$332K	Buy	+7,131	New	+$262K	0.01%	617

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Winton Group's LENZ Position: Q4 2025 in Review

Winton Group sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 7,131 shares — an estimated $332K sold.

Winton Group first reported a position in LENZ in Q3 2025 and held it in 1 quarter. The position peaked at $332K in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

Winton Group reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
Winton Group sold 7,131 LENZ Therapeutics shares in Q4 2025, an estimated $332K.
Winton Group first reported a position in LENZ Therapeutics in Q3 2025 and held it in 1 quarter.
Winton Group's LENZ Therapeutics position peaked at $332K in Q3 2025.
160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Winton Group's 13F filing for Q4 2025, filed 11 Feb 2026.